Cargando…

Screening of Fenofibrate-Simvastatin Solid Dispersions in the Development of Fixed-Dose Formulations for the Treatment of Lipid Disorders

The combination of statins and fibrates in the treatment of lipid abnormalities effectively regulates individual lipid fraction levels. In this study, the screening and assessment of the physicochemical properties of simvastatin-fenofibrate solid dispersions were performed. Fenofibrate and simvastat...

Descripción completa

Detalles Bibliográficos
Autores principales: Górniak, Agata, Czapor-Irzabek, Hanna, Złocińska, Adrianna, Gawin-Mikołajewicz, Agnieszka, Karolewicz, Bożena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9962408/
https://www.ncbi.nlm.nih.gov/pubmed/36839925
http://dx.doi.org/10.3390/pharmaceutics15020603
_version_ 1784895997262954496
author Górniak, Agata
Czapor-Irzabek, Hanna
Złocińska, Adrianna
Gawin-Mikołajewicz, Agnieszka
Karolewicz, Bożena
author_facet Górniak, Agata
Czapor-Irzabek, Hanna
Złocińska, Adrianna
Gawin-Mikołajewicz, Agnieszka
Karolewicz, Bożena
author_sort Górniak, Agata
collection PubMed
description The combination of statins and fibrates in the treatment of lipid abnormalities effectively regulates individual lipid fraction levels. In this study, the screening and assessment of the physicochemical properties of simvastatin-fenofibrate solid dispersions were performed. Fenofibrate and simvastatin were processed using the kneading method in different weight ratios, and the resulting solid dispersions were assessed using differential scanning calorimetry (DSC), X-ray powder diffractometry (XRPD), Fourier-transform infrared spectroscopy (FTIR), scanning electron microscopy (SEM), contact angle, as well as dissolution tests. The obtained results confirmed the formation of a simple eutectic phase diagram, with a eutectic point containing 79 wt% fenofibrate and 21 wt% simvastatin, lack of chemical interactions between the ingredients, and simvastatin impact on improving fenofibrate dissolution profile, due to the formation of crystalline solid dispersions by the kneading method.
format Online
Article
Text
id pubmed-9962408
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99624082023-02-26 Screening of Fenofibrate-Simvastatin Solid Dispersions in the Development of Fixed-Dose Formulations for the Treatment of Lipid Disorders Górniak, Agata Czapor-Irzabek, Hanna Złocińska, Adrianna Gawin-Mikołajewicz, Agnieszka Karolewicz, Bożena Pharmaceutics Article The combination of statins and fibrates in the treatment of lipid abnormalities effectively regulates individual lipid fraction levels. In this study, the screening and assessment of the physicochemical properties of simvastatin-fenofibrate solid dispersions were performed. Fenofibrate and simvastatin were processed using the kneading method in different weight ratios, and the resulting solid dispersions were assessed using differential scanning calorimetry (DSC), X-ray powder diffractometry (XRPD), Fourier-transform infrared spectroscopy (FTIR), scanning electron microscopy (SEM), contact angle, as well as dissolution tests. The obtained results confirmed the formation of a simple eutectic phase diagram, with a eutectic point containing 79 wt% fenofibrate and 21 wt% simvastatin, lack of chemical interactions between the ingredients, and simvastatin impact on improving fenofibrate dissolution profile, due to the formation of crystalline solid dispersions by the kneading method. MDPI 2023-02-10 /pmc/articles/PMC9962408/ /pubmed/36839925 http://dx.doi.org/10.3390/pharmaceutics15020603 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Górniak, Agata
Czapor-Irzabek, Hanna
Złocińska, Adrianna
Gawin-Mikołajewicz, Agnieszka
Karolewicz, Bożena
Screening of Fenofibrate-Simvastatin Solid Dispersions in the Development of Fixed-Dose Formulations for the Treatment of Lipid Disorders
title Screening of Fenofibrate-Simvastatin Solid Dispersions in the Development of Fixed-Dose Formulations for the Treatment of Lipid Disorders
title_full Screening of Fenofibrate-Simvastatin Solid Dispersions in the Development of Fixed-Dose Formulations for the Treatment of Lipid Disorders
title_fullStr Screening of Fenofibrate-Simvastatin Solid Dispersions in the Development of Fixed-Dose Formulations for the Treatment of Lipid Disorders
title_full_unstemmed Screening of Fenofibrate-Simvastatin Solid Dispersions in the Development of Fixed-Dose Formulations for the Treatment of Lipid Disorders
title_short Screening of Fenofibrate-Simvastatin Solid Dispersions in the Development of Fixed-Dose Formulations for the Treatment of Lipid Disorders
title_sort screening of fenofibrate-simvastatin solid dispersions in the development of fixed-dose formulations for the treatment of lipid disorders
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9962408/
https://www.ncbi.nlm.nih.gov/pubmed/36839925
http://dx.doi.org/10.3390/pharmaceutics15020603
work_keys_str_mv AT gorniakagata screeningoffenofibratesimvastatinsoliddispersionsinthedevelopmentoffixeddoseformulationsforthetreatmentoflipiddisorders
AT czaporirzabekhanna screeningoffenofibratesimvastatinsoliddispersionsinthedevelopmentoffixeddoseformulationsforthetreatmentoflipiddisorders
AT złocinskaadrianna screeningoffenofibratesimvastatinsoliddispersionsinthedevelopmentoffixeddoseformulationsforthetreatmentoflipiddisorders
AT gawinmikołajewiczagnieszka screeningoffenofibratesimvastatinsoliddispersionsinthedevelopmentoffixeddoseformulationsforthetreatmentoflipiddisorders
AT karolewiczbozena screeningoffenofibratesimvastatinsoliddispersionsinthedevelopmentoffixeddoseformulationsforthetreatmentoflipiddisorders